7/28/2019 GLIOMAS.ORG NEWSLETTERS 2013 Vol 1 (2)

1/3

7/28/2019 GLIOMAS.ORG NEWSLETTERS 2013 Vol 1 (2)

2/3

GLIOMAS.ORG NEWSLETTERS

__________________________________________________________________________________________________________________________

Volume 1 (2), May 2013.

www.gliomas.org 2

IMMUNOTHERAPY UPDATES

Cell-based Immunotherapy Against Gliomas: From Bench toBedside

Researchers from Massachusetts General Hospital, Boston,

Massachusetts, USA and Leiden University Medical Center,

Leiden, The Netherlands discussed advances in active, passive,

and vaccine-based immunotherapeutic strategies for gliomas

both at the bench and in the clinic. At present these treatmentshave not been effective in preventing disease progression.

Bovenberg MS, Degeling MH, Tannous BA.http://www.ncbi.nlm.nih.gov/pubmed/23648695. Mol Ther. 2013May 7. doi: 10.1038/mt.2013.80.

CARCINOGENESIS

Radiation from cellular and cordless phones is a probablehuman carcinogen (New review).

Recent analyses not considered in the 2011 study by the World

Health Organization, International Agency for Research on Can-

cer (IARC) find that brain tumor risk is significantly elevated for

those who have used mobile phones for at least a decade.Those who begin using either cordless or mobile phones regu-

larly before age 20 have greater than a fourfold increased risk

of ipsilateral glioma.

Davis DL, Kesari S, Soskolne CL, Miller AB, Stein Y. Swedishreview strengthens grounds for concluding that radiation fromcellular and cordless phones is a probable human carcinogen.Pathophysiology. 2013 May 7. doi:pii: S0928-4680(13)00003-5.10.1016/j.pathophys.2013.03.001.

EXPERIMENTAL PHARMACOLOGY

Predicting drug distribution

Convection-enhanced delivery (CED) is a technique that delivers

therapeutic agents directly and effectively into the brain paren-

chyma. Computational simulations can be useful to predict drug

distribution prior to CED. Results of such simulated experiments

compared in vivo experiments in the non-human primate brain-

stem suggest that simulation methodologies can be applied.

Sugiyama SI, Saito R, Funamoto K, Nakayama T, Sonoda Y,Yamashita Y, Inoue T, Kumabe T, Hayase T, Tominaga T.Computational simulation of convection enhanced drug deliveryin the non-human primate brainstem: a simple model predictingthe drug distribution. Neurol Res. 2013 May 7. [Epub ahead ofprint]. PMID: 23676199

ALTERNATIVE THERAPY

Caloric restriction reduces edema and prolongs survival in a

mouse glioma model.

Caloric restriction (CR) might be and effective natural therapy

to improves health, promotes longevity, and reduce both the

incidence and growth of many tumor types. It was found that

CR attenuated edema and promoted survival in a mouse glioma

model. The authors suggested that CR can be effective for re-

current gliomas through alleviating associated edema.

Jiang YS, Wang FR Caloric restriction reduces edema andprolongs survival in a mouse glioma model. J Neurooncol. 2013May 24. [Epub ahead of print] PMID:23703297

NANOPHARMACOLOGY

Superparamagnetic nano-carrier for drug delivery

Anew magnetic drug carrier was fabricated with octadecylquaternized caroxymethyl chitosan (OQCMC), hydrophobicFe3O4 ferrofluid and cholesterol, and a uniform diameter of20 nm. This magnetic carrier released plaxitaxel for more than

20 d in vitro and maintained high drug concentration in mag-

netically targeted areas. It seems promising for local chemo-

therapy to brain tumors.

Zhao M, Li A, Chang J, Fu X, Zhang Z, Yan R, Wang H, Liang S.Develop a novel superparamagnetic nano-carrier for drugdelivery to brain glioma.Drug Deliv. 2013 May 23.

EPIDEMIOLOGY

Early life exposures and the risk of adult glioma

Early exposure to childhood infections may reduce the risk of

glioma onset in children and adults. The mechanism associated

may be by stimulating immune development since, compared

to first-borns, individuals with older siblings had a significantly

lower risk.

Anic GM, Madden MH, Sincich K, Thompson RC, Nabors LB,Olson JJ, Larocca RV, Browning JE, Pan E, Egan KM Early lifeexposures and the risk of adult glioma.. Eur J Epidemiol. 2013May 17. [Epub ahead of print] PMID: 23681776

Comparison between poor and long-term survivors withglioblastoma

An Autralian study found that age, performance status, extent

of resection and clinical trial participation were independently

associated with survival. Of particular importance clinical trial

participation was associated with long term survival (>24

months).

Field KM, Rosenthal MA, Yilmaz M, Tacey M, Drummond K.Comparison between poor and long-term survivors withglioblastoma: Review of an Australian dataset. Asia Pac J ClinOncol. 2013 May 22. doi: 10.1111/ajco.12076. [Epub ahead ofprint] PMID: 23701649

CLINICAL TRIALS

Phase I study of temozolomide combined with oral etoposide

A multicenter phase I study established the recommended dose

(RD) of the combination therapy with temozolomide (TMZ) and

oral etoposide (VP-16). The RD for phase II trial in children with

malignant glial tumors is TMZ 150 mg/m2 for 5 days and VP-16

50 mg/m2 for 10 days every 28 days. The study included chil-

7/28/2019 GLIOMAS.ORG NEWSLETTERS 2013 Vol 1 (2)

3/3

GLIOMAS.ORG NEWSLETTERS

_____________________________________________________________________________________________________________________________

Volume 1 (2), May 2013.

www.gliomas.org

dren with relapsed or refractory malignant glioma and brain-

stem glioma at diagnosis.

Ruggiero A, Rizzo D, Attin G, Lazzareschi I, Maurizi P, Ridola V,Mastrangelo S, Migliorati R, Bertolini P, Colosimo C, Riccardi RPhase I study of temozolomide combined with oral etoposide inchildren with malignant glial tumors. J Neurooncol. 2013 May 12.[Epub ahead of print] PMID: 23666235

EXPERIMENTAL THERAPY

Tackling Resistant Glioma Cells by Cold AtmosphericPlasma (CAP)

Sketch of the plasma production on a Surface Micro-Discharge(SMD) electrode. The plasma discharge is ignited on the SMDelectrode and the reactive species are produced in the plasma byelectrons from air molecules. The produced reactive speciesreach the sample by diffusion and induce there biologicalreactions.

The alkylating agent temozolomide (TMZ) that improves the

overall survival in patients with malignant gliomas is often inne-

fective dut to intrinsic and acquired resistance of glioma cells.

CAP, a partially ionized gas, restored theresponsiveness of resistant glioma cells towards

temozolomide (TMZ) therapy. Thus, CAP migh be apromising candidate for combination therapy.

Kritzer J, Boxhammer V, Schfer A, Shimizu T, Klmpfl TG, LiYF, Welz C, Schwenk-Zieger S, Morfill GE, Zimmermann JL,Schlegel J. Restoration of Sensitivity in Chemo - ResistantGlioma Cells by Cold Atmospheric Plasma. PLoS One. 2013 May21;8(5):e64498. Print 2013. PMID: 23704990

II Anticancer Drugs

Meeting

22-23 August, 2013

Stockholm, Sweden

Confirmed Speakers from US

Germany

France

UK

Sweden

Egypt

Australia

Israel

Japan

Saudi Arabia

Mexico

Russia

and other countries will pre-

sent their work

Early bird registration deadlineMay 22, 2013

www.anticancerdrugs.org/2013

www.gliomas.org/shop